Click for best price
Kidney Cancer Renal Cell Carcinoma RCC Drugs Market Size, Share 2023
| Market size in 2022 |
US$ 5255.3 million
|
Forecast Market size by 2029 |
US$ 6545.8 million
|
| Growth Rate |
CAGR of 3.2% |
Number of Pages |
66 Pages |
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs. This report contains market size and forecasts of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs in global, including the following market information:
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market was valued at US$ 5255.3 million in 2022 and is projected to reach US$ 6545.8 million by 2029, at a CAGR of 3.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Afinitor (Everolimus) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs include Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, Roche Holding AG, Glaxosmithkline Plc, Novartis Ag and Pfizer, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, by Type, 2022 (%)
Afinitor (Everolimus)
Avastin (Bevacizumab)
Cabomety (Cabozantinib)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinic
Others
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Active Biotech Ab
Amgen
Bayer AG
Cipla Limited
Roche Holding AG
Glaxosmithkline Plc
Novartis Ag
Pfizer, Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, market overview.
Chapter 2: Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size in revenue.
Chapter 3: Detailed analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 5255.3 million
|
| Forecast Market size by 2029 |
US$ 6545.8 million
|
| Growth Rate |
CAGR of 3.2% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
66 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Overall Market Size
2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size: 2022 VS 2029
2.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players in Global Market
3.2 Top Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies Ranked by Revenue
3.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Companies
3.4 Top 3 and Top 5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players in Global Market
3.6.1 List of Global Tier 1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Markets, 2022 & 2029
4.1.2 Afinitor (Everolimus)
4.1.3 Avastin (Bevacizumab)
4.1.4 Cabomety (Cabozantinib)
4.1.5 Inlyta (Axitinib)
4.1.6 Nexavar (Sorafenib)
4.1.7 Proleukin (Aldesleukin)
4.1.8 Torisel (Temsirolimus)
4.1.9 Sutent (Sunitinib)
4.1.10 Votrient (Pazopanib)
4.2 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue & Forecasts
4.2.1 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2023
4.2.2 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2024-2029
4.2.3 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue & Forecasts
5.2.1 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2023
5.2.2 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2024-2029
5.2.3 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2022 & 2029
6.2 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue & Forecasts
6.2.1 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2023
6.2.2 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2024-2029
6.2.3 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2029
6.3.2 US Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.3.3 Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.3.4 Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2029
6.4.2 Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.4.3 France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.4.4 U.K. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.4.5 Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.4.6 Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.4.8 Benelux Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2029
6.5.2 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.5.3 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.5.4 South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.5.6 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2029
6.6.2 Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.6.3 Argentina Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2029
6.7.2 Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.7.3 Israel Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
6.7.5 UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2018-2029
7 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies Profiles
7.1 Active Biotech Ab
7.1.1 Active Biotech Ab Company Summary
7.1.2 Active Biotech Ab Business Overview
7.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.1.4 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2018-2023)
7.1.5 Active Biotech Ab Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Company Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.2.4 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2018-2023)
7.2.5 Amgen Key News & Latest Developments
7.3 Bayer AG
7.3.1 Bayer AG Company Summary
7.3.2 Bayer AG Business Overview
7.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.3.4 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2018-2023)
7.3.5 Bayer AG Key News & Latest Developments
7.4 Cipla Limited
7.4.1 Cipla Limited Company Summary
7.4.2 Cipla Limited Business Overview
7.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.4.4 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2018-2023)
7.4.5 Cipla Limited Key News & Latest Developments
7.5 Roche Holding AG
7.5.1 Roche Holding AG Company Summary
7.5.2 Roche Holding AG Business Overview
7.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.5.4 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2018-2023)
7.5.5 Roche Holding AG Key News & Latest Developments
7.6 Glaxosmithkline Plc
7.6.1 Glaxosmithkline Plc Company Summary
7.6.2 Glaxosmithkline Plc Business Overview
7.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.6.4 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2018-2023)
7.6.5 Glaxosmithkline Plc Key News & Latest Developments
7.7 Novartis Ag
7.7.1 Novartis Ag Company Summary
7.7.2 Novartis Ag Business Overview
7.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.7.4 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2018-2023)
7.7.5 Novartis Ag Key News & Latest Developments
7.8 Pfizer, Inc.
7.8.1 Pfizer, Inc. Company Summary
7.8.2 Pfizer, Inc. Business Overview
7.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.8.4 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2018-2023)
7.8.5 Pfizer, Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Opportunities & Trends in Global Market
Table 2. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers in Global Market
Table 3. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints in Global Market
Table 4. Key Players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs in Global Market
Table 5. Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Type
Table 9. List of Global Tier 1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Active Biotech Ab Company Summary
Table 31. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 32. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Active Biotech Ab Key News & Latest Developments
Table 34. Amgen Company Summary
Table 35. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 36. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Amgen Key News & Latest Developments
Table 38. Bayer AG Company Summary
Table 39. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 40. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Bayer AG Key News & Latest Developments
Table 42. Cipla Limited Company Summary
Table 43. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 44. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Cipla Limited Key News & Latest Developments
Table 46. Roche Holding AG Company Summary
Table 47. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 48. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Roche Holding AG Key News & Latest Developments
Table 50. Glaxosmithkline Plc Company Summary
Table 51. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 52. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Glaxosmithkline Plc Key News & Latest Developments
Table 54. Novartis Ag Company Summary
Table 55. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 56. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Novartis Ag Key News & Latest Developments
Table 58. Pfizer, Inc. Company Summary
Table 59. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 60. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Pfizer, Inc. Key News & Latest Developments
List of Figures
Figure 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Segment by Type in 2022
Figure 2. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Segment by Application in 2022
Figure 3. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2022
Figure 8. By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 16. US Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 28. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
